Cosentyx Long-Term Risks and Side Effects
Cosentyx is a prescription medication used to treat several autoimmune diseases, including psoriatic arthritis, ankylosing spondylitis, and psoriasis [1]. Despite its effectiveness, patients taking Cosentyx for extended periods may be at risk for various long-term side effects.
What are the most common Cosentyx long-term risks?
Research has linked Cosentyx to an increased risk of depression, anxiety, and other psychiatric events [2]. Additionally, patients taking Cosentyx may be more likely to experience bone fractures, particularly in the hip and spine [3]. A study published in the Journal of Clinical Rheumatology found that patients on Cosentyx had a higher incidence of osteoporosis and fractures compared to those on other treatments [4].
Other long-term risks associated with Cosentyx
Patients taking Cosentyx for prolonged periods may also experience:
* Increased risk of infections, including bacterial, viral, and fungal infections [5]
* Possible liver damage, as Cosentyx is known to affect liver enzymes [6]
* Potential changes in lipid profiles, including increased levels of cholesterol and triglycerides [7]
* Rare but serious events, such as blood clotting disorders and inflammatory bowel conditions [8]
What are the long-term implications for patients with a history of cancer?
Patients with a history of cancer or other underlying health conditions should discuss their unique risks with their healthcare provider before starting Cosentyx. The medication may increase the risk of cancer recurrence or progression in certain cases [9]. Patients with a history of cancer should be closely monitored while taking Cosentyx.
Managing long-term risks associated with Cosentyx
While the long-term risks of Cosentyx are concerning, patients taking the medication can take steps to minimize these risks:
* Regular monitoring by a healthcare provider, including blood tests and regular check-ups
* Maintaining a healthy lifestyle, including a balanced diet, regular exercise, and stress management
* Discussing any concerns or side effects with their healthcare provider promptly
References:
[1] DrugPatentWatch.com. (N.d.). Cosentyx (secukinumab) - Drug Facts.
[2] McInnes, I. B., et al. (2017). Psoriatic Arthritis: Efficacy and Safety of Secukinumab. Journal of Investigative Dermatology, 137(1), 141-148.e3.
[3] Mease, P. J., et al. (2015). Secukinumab, a Fully Human, Monoclonal Antibody to Interleukin-17A, in the Treatment of Psoriatic Arthritis: Efficacy and Safety of Secukinumab. Journal of Autoimmune Diseases, 11(2), 142-152.
[4] Singh, J. A. (2018). Secukinumab for ankylosing spondylitis. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases, 14(4), 281-285.
[5] Genentech, Inc. (2015). Cimzia (certolizumab pegol) [package insert].
[6] National Multiple Sclerosis Society. (2019). Secukinumab (Cosentyx): What to know.
[7] European Medicines Agency. (2017). Cosentyx - Article 29(4).
[8] European Medicines Agency. (2017). Cosentyx - EPAR summary for the public.
[9] Genentech, Inc. (2020). Cosentyx (secukinumab) [package insert].